Inflammation conjoins differentiation and resistance in AML
In this issue of Blood, Allen and colleagues provide insights into the mechanisms of resistance to MDM2 and BCL-2 inhibitors such as idasanutlin and veneto
Related Articles
Clonal hematopoiesis landscape in frequent blood donors
Key PointsCH analysis of a unique and uniform cohort of exclusively healthy individuals exposed to a novel type of selection pressure was conducted.Novel E
A novel way for transglutaminase 2 to mitigate liver damage
In this issue of Blood, Wei et al demonstrate that tissue transglutaminase (TG2) can help mitigate liver damage by dynamically altering the structure of ex
Chromatin dynamics in CLL: a matter of balance
In this issue of Blood, Chapaprieta et al introduce a novel prognostic score in chronic lymphocytic leukemia (CLL) based on the balance of de novo…
Blitzing ALL with blinatumomab
In this issue of Blood, Bassan et al1 report the results of the phase 2 Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) LAL2317 trial following
Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study
Key PointsTo improve MRD response and outcome, blinatumomab was added to the early consolidation of a risk-oriented program for adult Ph– B-ALL.After blina
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients
Background. The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last
Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia
Key PointsRegulatory regions undergoing de novo chromatin activation in CLL are associated with both progressive and indolent disease.A balance score betwe